Quanterix
One Kendall Square
Building 1400W, 2nd Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-301-9400
Fax: 617-301-9401
Website: http://www.quanterix.com/
Email: info@quanterix.com
213 articles about Quanterix
-
Quanterix’ Simoa Technology Supports 42 Scientific Presentations at MSVirtual2020
9/10/2020
Company’s ultra-sensitive platform continues to facilitate important advances that harness biomarkers to identify, monitor and validate treatment pathways for Multiple Sclerosis (MS) BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa® technology has been used by leading research teams to power
-
Quanterix Prices Public Offering of Common Stock - Aug 07, 2020
8/7/2020
Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced the pricing of its previously announced underwritten public offering of 2,651,108 shares of its common stock at a public offering price of $32.00 per share.
-
Quanterix Announces Proposed Public Offering of Common Stock - Aug 06, 2020
8/6/2020
Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced that it has commenced an underwritten public offering of its common stock.
-
Quanterix Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
8/3/2020
Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2020 after the close of trading on Tuesday, August 4, 2020. Company management will host a conference call at 5:00 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by
-
Quanterix sNfL Assay and Simoa Technology First to Measure Neuronal Injury in COVID-19 Patients’ Blood
7/29/2020
Findings offer first-time evidence of neuro-axonal damage in mild-to-moderate cases of SARS-CoV-2 and validate serum neurofilament light chain (sNfL) as a highly specific biomarker to measure and monitor damage during and post infection BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that quantitative testing using its sN
-
Quanterix to Participate in Alzheimer’s Association International Conference (AAIC) 2020
7/27/2020
Company’s ultra-sensitive Simoa® technology powers more than 50 posters and presentations on display during this year’s virtual program; attendees can be among the first to experience Simoa p-tau181 assay for improved study of Alzheimer’s disease and visit virtual exhibitor booth
-
Quanterix Corporation CEO to Present at MassBio: Possible Talk Series
6/26/2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Chairman and Chief Executive Officer of Quanterix and Founder of the non-profit Powering Precision Health (PPH), will participate in the MassBio: Possible Talk series on June 26, 2020 at 10 a.m. EDT
-
Quanterix to Host Virtual Annual Meeting of Stockholders
6/11/2020
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of meeting participants. The Annual Meeting will be held in a virtual-onl
-
Quanterix’ Simoa Technology Sets New Standard in Protein Detection
5/13/2020
Quanterix’ Simoa Technology Sets New Standard in Protein Detection New research published in Lab on a Chip demonstrates 100x sensitivity improvement on Simoa; marks significant advancement in sensitivity for industry leading detection platform
-
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2019
3/9/2020
Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2019. “We’re pleased to close out another year of compelling growth, product launches, productive capital raises, key hires and technology adoption, mark
-
Quanterix Corporation to Release Fourth Quarter 2019 Financial Results on March 9, 2020 and Present at Multiple Upcoming Healthcare Conferences
2/21/2020
Quanterix Corporation announced that it will release its financial results for fourth quarter 2019 after the close of trading on Monday, March 9, 2020.
-
Quanterix Corporation Releases Operating Results for Third Quarter 2019
11/6/2019
Strong revenue growth and successful early launch of new HD-X Analyzer
-
Siemens Healthineers Enters into License and Supply Arrangement with Quanterix for Access to Neurofilament Light (Nf-L) Antibodies to Develop Nf-L Assays
11/4/2019
Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics.
-
Quanterix to Release Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
10/22/2019
Quanterix Corporation announced that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019.
-
Quanterix Announces Recipients of Annual Accelerator Grant Program
10/3/2019
Winners of the second annual call for research proposals focuses on predictive biomarkers of neurodegeneration, neurological injury and inflammation in relation to cognitive functioning and brain connectivity among breast cancer survivors
-
Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019
9/11/2019
Record-breaking number of presentations and abstracts at International Multiple Sclerosis conference demonstrates promise and relevance of Neurofilament light chain (Nf-L) as a reliable disease biomarker for MS
-
Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
8/13/2019
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares
-
Quanterix Prices Public Offering of Common Stock
8/9/2019
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share.
-
Quanterix Corporation Releases Operating Results for Second Quarter 2019
8/6/2019
$13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increase
-
Quanterix to Present at the Canaccord Genuity 39th Annual Growth Conference
7/31/2019
Hrusovsky, who will also share remarks at an investor dinner the prior evening hosted by Canaccord Genuity to discuss company momentum in advancing Alzheimer’s treatments and diagnoses, will also be available for one-on-one meetings during the conference.